About Amunix

Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Founded in 2006, Amunix’ pipeline products are based on its proprietary XTEN® half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T cell engager platform technologies. Located in Mountain View, CA, Amunix is progressing the development of its internal pipel...

Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Founded in 2006, Amunix’ pipeline products are based on its proprietary XTEN® half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T cell engager platform technologies. Located in Mountain View, CA, Amunix is progressing the development of its internal pipeline and also has ongoing collaborations with a number of established and emerging biopharma corporations harnessing these delivery technologies in a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing.

Contact Amunix

Phone Number
+1 650 428 1800

More About Amunix

Therapeutic Areas
  • Oncology
Technologies
  • Drug delivery
Company Type
  • Biotechnology – Therapeutics
State of Ownership
  • Private
Go to the profile of Charles Thiede

Charles Thiede

CEO & Co-Founder, Zapnito

Go to the profile of Jen Thoroughgood

Jen Thoroughgood

Chief Product Officer, Zapnito

Go to the profile of Samia Burridge

Samia Burridge

Business Development Manager, Global Sponsorship, Nature Research Group

Go to the profile of Ericka Moore

Ericka Moore

Director of Sales , SOLABS

C

Claire Hyder

Project Development Manager, Cancer Research Technology

Go to the profile of Carmen Ramirez

Carmen Ramirez

Sales Account Executive, Springer Nature

Go to the profile of Albany A. Cordova Martins

Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature